Bénédicte Roquebert
Virbac (France)(FR)
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, HIV Research and Treatment, SARS-CoV-2 and COVID-19 Research, SARS-CoV-2 detection and testing, HIV/AIDS Research and Interventions
Most-Cited Works
- → Rapid spread of the SARS-CoV-2 Delta variant in some French regions, June 2021(2021)875 cited
- → High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment‐Experienced Patients Infected with Multidrug‐Resistant HIV: Results of the ANRS 139 TRIO Trial(2009)237 cited
- → In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors(2008)128 cited
- → HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro(2008)126 cited
- → Human Immunodeficiency Virus Type 1 (HIV-1) Plasma Load Discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Assays(2007)82 cited
- → Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients(2006)60 cited
- → Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients(2008)58 cited
- → Evaluation of an Upgraded Version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Test for HIV-1 Load Quantification(2010)49 cited
- → Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen(2008)43 cited
- → Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients(2009)42 cited